- Home
- LRMR vs EARN Comparison
LRMR vs EARN Comparison
Compare LRMR & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- EARN
- Stock Information
- Founded
- LRMR N/A
- EARN 2012
- Country
- LRMR United States
- EARN United States
- Employees
- LRMR N/A
- EARN N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- EARN Real Estate Investment Trusts
- Sector
- LRMR Health Care
- EARN Real Estate
- Exchange
- LRMR Nasdaq
- EARN Nasdaq
- Market Cap
- LRMR 204.9M
- EARN 223.5M
- IPO Year
- LRMR N/A
- EARN 2013
- Fundamental
- Price
- LRMR $3.88
- EARN $5.93
- Analyst Decision
- LRMR Strong Buy
- EARN Buy
- Analyst Count
- LRMR 7
- EARN 2
- Target Price
- LRMR $17.86
- EARN $6.13
- AVG Volume (30 Days)
- LRMR 892.3K
- EARN 282.4K
- Earning Date
- LRMR 08-06-2025
- EARN 08-11-2025
- Dividend Yield
- LRMR N/A
- EARN 16.22%
- EPS Growth
- LRMR N/A
- EARN N/A
- EPS
- LRMR N/A
- EARN N/A
- Revenue
- LRMR N/A
- EARN $35,893,000.00
- Revenue This Year
- LRMR N/A
- EARN $3.72
- Revenue Next Year
- LRMR N/A
- EARN $18.60
- P/E Ratio
- LRMR N/A
- EARN N/A
- Revenue Growth
- LRMR N/A
- EARN 43.30
- 52 Week Low
- LRMR $1.61
- EARN $4.33
- 52 Week High
- LRMR $9.88
- EARN $7.14
- Technical
- Relative Strength Index (RSI)
- LRMR 69.65
- EARN 55.19
- Support Level
- LRMR $3.11
- EARN $5.85
- Resistance Level
- LRMR $4.01
- EARN $6.05
- Average True Range (ATR)
- LRMR 0.27
- EARN 0.09
- MACD
- LRMR 0.03
- EARN -0.00
- Stochastic Oscillator
- LRMR 85.64
- EARN 54.55
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.